11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Pfizer Inc (PFE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 373,919 | $10,664,170 | +1% | 1.53% |
| 2. | Bailard Inc Thomas Bailard | 60,099 | $1,714,023 | +17% | 0.03% |
| 3. | Lee Munder Capital Group Lee Munder | 43,537 | $1,241,675 | -1% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.34 | 38,000 | $1,000,920.00 | 429,173 | 2026-08-12 | Filing | |
| $25.46 | 39,231 | $998,821.26 | 66,938 | 2026-08-05 | Filing | |
| $25.52 | 37,632 | $960,368.64 | 37,632 | 2026-08-05 | Filing | |
| $25.65 | 19,457 | $499,072.05 | 27,707 | 2025-02-13 | Filing | |
| $28.24 | 1,000 | $28,240.00 | 10,000 | 2024-10-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.40 | 3,278 | $83,261.20 | 28,611 | 2026-08-05 | Filing | |
| $25.70 | 2,000 | $51,400.00 | 31,397 | 2026-06-09 | Filing | |
| $25.93 | 2,500 | $64,825.00 | 11,850 | 2025-03-04 | Filing | |
| $28.66 | 5,154 | $147,713.64 | 8,582 | 2024-08-13 | Filing | |
| $40.02 | 9,912 | $396,678.24 | 9,003 | 2023-03-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,021,329 | $342,848,306 | 0.41% | |
| 2. | 7,514,902 | $214,325,005 | 0.21% | |
| 3. | 3,761,718 | $107,284,197 | 0.94% | |
| 4. | 4,132,122 | $107,029,857 | 0.16% | |
| 5. | 2,077,952 | $59,263,191 | 0.3% |
News See All
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger.
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?
Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts of their pharmaceutical portfolios.
Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You?
Pfizer Inc. (NYSE:PFE) closed at $28.40 on October 12.
Pfizer Is Trading at Less Than 10 Times Earnings. But Is the Stock Actually Cheap?
Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking inexpensive.
Can Pfizer (PFE) Turn a Forward P/E Discount into Real Returns?
Pfizer Inc. (NYSE:PFE) is up 11.4% year-to-date and leads to a classic value-versus-risk setup.
10 Best Stocks for Beginners with Little Money
In this article, we look at the 10 Best Stocks for Beginners with Little Money. A small starting balance changes how investors enter the market, but it does not change what makes a business valuable.
Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?
Pfizer Inc. (NYSE:PFE) looks cheap based on its forward P/E, but its earnings outlook helps explain the discount.
Pfizer (PFE) Trades Below Its Own Average Multiple, Is It Cheap for a Reason?
Pfizer (NYSE:PFE) raised its revenue guidance in the second quarter of 2026, held its earnings guidance and announced another round of cost cuts. It also reported a loss of $0.04 a share.
Becton Dickinson (BDX) Joins Trump Tariff Exemption Scramble with $19B Investment Plan
U.S. medical device company Becton Dickinson ($BDX) has agreed to invest $19 billion in the U.S. over several years, the company announced in a sta...